These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 16189100)
1. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Bogdanovich T; Ednie LM; Shapiro S; Appelbaum PC Antimicrob Agents Chemother; 2005 Oct; 49(10):4210-9. PubMed ID: 16189100 [TBL] [Abstract][Full Text] [Related]
2. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Kosowska K; Hoellman DB; Lin G; Clark C; Credito K; McGhee P; Dewasse B; Bozdogan B; Shapiro S; Appelbaum PC Antimicrob Agents Chemother; 2005 May; 49(5):1932-42. PubMed ID: 15855516 [TBL] [Abstract][Full Text] [Related]
3. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Bogdanovich T; Clark C; Ednie L; Lin G; Smith K; Shapiro S; Appelbaum PC Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565 [TBL] [Abstract][Full Text] [Related]
4. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Jones ME Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372 [TBL] [Abstract][Full Text] [Related]
5. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents. Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections. Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316 [TBL] [Abstract][Full Text] [Related]
7. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975 [TBL] [Abstract][Full Text] [Related]
8. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis. Lin G; Appelbaum PC Diagn Microbiol Infect Dis; 2008 Feb; 60(2):233-5. PubMed ID: 17997257 [TBL] [Abstract][Full Text] [Related]
9. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types. Farrell DJ; Flamm RK; Sader HS; Jones RN Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474 [TBL] [Abstract][Full Text] [Related]
10. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. Barber KE; Werth BJ; Ireland CE; Stone NE; Nonejuie P; Sakoulas G; Pogliano J; Rybak MJ J Antimicrob Chemother; 2014 Nov; 69(11):3006-10. PubMed ID: 24990867 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. Pillar CM; Aranza MK; Shah D; Sahm DF J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646 [TBL] [Abstract][Full Text] [Related]
12. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria. Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Fritsche TR; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study. Walkty A; Adam HJ; Laverdière M; Karlowsky JA; Hoban DJ; Zhanel GG; Diagn Microbiol Infect Dis; 2011 Mar; 69(3):348-55. PubMed ID: 21353964 [TBL] [Abstract][Full Text] [Related]
16. Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin. Hoellman DB; Pankuch GA; Appelbaum PC Antimicrob Agents Chemother; 2004 Oct; 48(10):4037-9. PubMed ID: 15388474 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Rouse MS; Steckelberg JM; Patel R Diagn Microbiol Infect Dis; 2007 Jul; 58(3):363-5. PubMed ID: 17449212 [TBL] [Abstract][Full Text] [Related]